OTUD5 and gastric cancer: Moreover, treatment of AGS gastric cancer cells with nutlin‐3a, a known p53 activator, led to a pronounced reduction in the protein levels of OTUD5 and GPX4 (Figure 4B), as well as an inhibition of cell proliferation (Figure S3A).